^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Biliary Tract Cancer

Related cancers:
2d
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine. (PubMed, Expert Opin Pharmacother)
For decades, the combination of gemcitabine with cisplatin (GemCis) has been the standard of care for palliative treatment. Due to the high frequency of targetable genetic alterations in BTC patients, there is a growing emphasis on obtaining tissue or liquid biopsy samples to identify markers like microsatellite instability and other actionable oncogenic driver genes. Early initiation of systemic therapies in combination with multimodal approaches is essential for maximizing survival outcomes in patients with BTC.
Review • Journal • IO biomarker
|
MSI (Microsatellite instability)
|
cisplatin • gemcitabine
2d
Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist. (PubMed, Clin Nephrol)
Collaboration between nephrologists and oncologists is crucial for optimizing treatment benefits and managing side effects. Further research is warranted to refine management strategies and to understand the clinical implications of hyperphosphatemia.
Journal
|
FGFR (Fibroblast Growth Factor Receptor)
|
Balversa (erdafitinib)
5d
Advances in target drugs and immunotherapy for biliary tract cancer. (PubMed, Expert Rev Gastroenterol Hepatol)
In the expert opinion, we discuss the problem of the scarcity of patients eligible for target therapies and how can clinical trials be designed to overcome this challenge. We also summarize the most promising trials that have the potential to change clinical practice both for immunotherapies and target drugs.
Review • Journal
|
KRAS (KRAS proto-oncogene GTPase) • FGFR (Fibroblast Growth Factor Receptor)
5d
Durvalumab plus cisplatin and gemcitabine as first line therapy for advanced biliary tract carcinoma (aBTC): a monocentric retrospective experience (AIOM 2024)
The data presented in this study are consistent with the results of TOPAZ1 trial. However about a third of patients do not respond to CHT or have a short response duration. In our experience both NLR and basal elevated AST/ALT seem to be associated with an improved mPFS and a better outcome but further studies are needed.
Retrospective data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)
|
TP53 mutation • KRAS mutation • TMB-H • TMB-L
|
TruSight Oncology 500 Assay
|
cisplatin • Imfinzi (durvalumab) • gemcitabine
5d
First results from the Italian cholangiocarcinoma dataset (ANITA): extended molecular profiling (EMP), access to targeted treatment (TT) and clinical characterization of FGFR2- rearranged and IDH1-mutated advanced biliary tract cancers (BTC) (AIOM 2024)
Among pts with EMP available, 64.2% had intrahepatic cholangiocarcinoma and 69.8% received CT1 (36.1% cisplatinum-gemcitabine). Despite a broader availability of EMP in advanced BTC in recent years, access to TT remains suboptimal even in referral Institutions. Our results demonstrate TT administration as a pivotal positive prognostic factor in a real-world setting, whilst FGFR2 or IDH1 alterations did not act as prognostic determinants per-se. Therefore, strategies aiming at improving the rate of patients receiving TT are warranted.
Clinical • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • FGFR2 mutation • FGFR2 fusion • IDH1 R132
|
FoundationOne® CDx
|
cisplatin • gemcitabine
5d
A Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab. (PubMed, Cancer Rep (Hoboken))
This report supports the clinical benefit of anti-EGFR antibodies for EGFR-amplified biliary tract cancers and the importance of genomic analysis in personalized therapy and drug resistance research.
Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR amplification
|
cisplatin • gemcitabine • Portrazza (necitumumab)
6d
Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. (PubMed, Clin Cancer Res)
Here, we developed a catalog of BTC PDXs which underwent comprehensive molecular profiling and therapeutic modeling. To date, this is one of the largest collections of BTC PDX models and will facilitate the development of personalized treatments for patients with these aggressive malignancies.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
10d
CIBI354A101: A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=368, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
IBI-354
12d
New P2 trial • Metastases
|
cisplatin • gemcitabine • Kaitanni (cadonilimab)
12d
Phase II study of Sintilimab combined with GS regimen for neoadjuvant treatment of locally advanced biliary tract cancer (BTC) (ChiCTR2400089592)
P2, N=38, Not yet recruiting, Shanghai Eastern Hepatobiliary Surgery Hospital; Shanghai Eastern Hepatobiliary Surgery Hospital
New P2 trial • Metastases
|
Tyvyt (sintilimab)
12d
New P2 trial • Metastases
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Ariely (adebrelimab)
18d
Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers. (PubMed, Cancer Sci)
The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.
Journal • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
22d
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (clinicaltrials.gov)
P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial primary completion date: Jun 2025 --> Jan 2026
Trial primary completion date • Patient reported outcomes
24d
New P2/3 trial • Metastases
|
5-fluorouracil • Focus V (anlotinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)
24d
Ginsenoside Rg3 activates the immune function of CD8+ T cells via circFOXP1-miR-4477a-PD-L1 axis to induce ferroptosis in gallbladder cancer. (PubMed, Arch Pharm Res)
Ferroptosis inhibitor Fer-1 administration could reverse the beneficial effects caused by Rg3 treatment while ferroptosis inducer Erastin treatment enhanced the effects...Rg3 inactivated the circFOXP1-miR-4477a-PD-L1 signaling axis to activate the immune function of CD8+ T cells, thereby inducing ferroptosis and apoptosis in GBC cells. This research recognizes the mechanism of Rg3-mediated anti-cancer effect and offers evidence for the potentiality of Rg3 in clinical application for GBC therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8)
|
PD-L1 overexpression
|
erastin
25d
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers (clinicaltrials.gov)
P=N/A, N=60, Recruiting, Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
cisplatin • Imfinzi (durvalumab) • gemcitabine
29d
New P2 trial
|
Sulanda (surufatinib) • Enweida (envafolimab)
29d
Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. (PubMed, J Hepatol)
Among patients with advanced BTC, ctDNA-based genotyping showed acceptable concordance with tissue genomic profiling. Liquid biopsy using ctDNA could be a valuable complement to tissue-based genomic analysis in BTC.
Journal • BRCA Biomarker • Circulating tumor DNA • Metastases • Discordant
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
BRCA2 mutation • BRCA1 mutation • HER-2 amplification • PIK3CA mutation • IDH1 mutation • MET amplification • FGFR2 mutation • FGFR2 fusion • MET mutation • PIK3CA amplification
|
AlphaLiquid® 100
|
cisplatin • gemcitabine
30d
New P2 trial • Metastases
|
Loqtorzi (toripalimab-tpzi) • oxaliplatin • Sulanda (surufatinib)
1m
Trial completion date • Metastases
|
cisplatin • gemcitabine • albumin-bound paclitaxel
1m
New trial • Minimal residual disease
1m
TranStar102: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=320, Recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Aug 2024 --> Feb 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative
|
Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)
1m
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer (clinicaltrials.gov)
P1, N=90, Active, not recruiting, Fujifilm Pharmaceuticals U.S.A., Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
liposomal gemcitabine (FF-10832)
1m
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
|
HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type
|
Avastin (bevacizumab) • cisplatin • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii)
1m
New trial • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
1m
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab. (PubMed, medRxiv)
Malignant cell states co-varied with distinct immune cell states, revealing diverse mechanisms of myeloid and T-cell mediated immune suppression, including M2 myeloid and terminally exhausted T cell programs that were induced by DKN-01/nivolumab. Here, we provide the first systematic classification of functionally annotated cell states in biliary tract cancer and provide new insight into resistance mechanisms to an immunotherapy combination that can inform the next generation of trials.
P2 data • Journal
|
DKK1 (dickkopf WNT signaling pathway inhibitor 1)
|
Opdivo (nivolumab) • sirexatamab (DKN-01)
1m
Expression of the large amino acid transporter SLC7A5/LAT1 on immune cells is enhanced in primary sclerosing cholangitis-associated cholangiocarcinoma and correlates with poor prognosis in cholangiocarcinoma. (PubMed, Hum Pathol)
These results underline the potential use of SLC7A5/LAT1 as a prognostic marker in BTC. Furthermore, the higher frequency of SLC7A5/LAT1 positive immune cells in PSC-BTC compared to sBTC may hint at the potential role of SLC7A5/LAT1 in inflammation-driven carcinogenesis.
Journal • Immune cell
|
CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • SLC7A5 (Solute Carrier Family 7 Member 5)
1m
Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3. (PubMed, Biomed Pharmacother)
Genetic and pharmacological MRP3 inhibition enhances the anti-CCA effect of several drugs, which constitutes a promising strategy to improve the response to chemotherapy in CCA patients.
Journal
|
ABCC3 (ATP Binding Cassette Subfamily C Member 3)
|
cisplatin • sorafenib • etoposide IV • mitoxantrone
1m
VISIONARY: Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (clinicaltrials.gov)
P=N/A, N=600, Active, not recruiting, Peking University | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Mar 2025 | Trial primary completion date: Feb 2024 --> Nov 2024
Enrollment closed • Trial completion date • Trial primary completion date • Real-world evidence • Tumor mutational burden • Real-world
|
FoundationOne® CDx
1m
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma (clinicaltrials.gov)
P2, N=34, Suspended, Zhejiang Cancer Hospital | Recruiting --> Suspended
Trial suspension • Surgery
|
AiRuiKa (camrelizumab) • Sulanda (surufatinib)
1m
Homologous recombination deficiency (HRD) in biliary carcinomas: clinical significance and correlation with platinum response (DGHO 2024)
In second-line treatment, no difference between an Irinotecan-based regimen and re-exposure to platinum-based agents (12.36 vs 10.13 months; HR 0.92; P=0.85) could be observed (HR 1.45; P=0.35). HRRm BTC patients showed a potential advantage in OS following platinum-based first-line chemotherapy, presumably attributed to enhanced opportunities for targetable co-alterations. Further investigation is needed to delineate HRD in the context of personalizing systemic therapies of BTC.
Clinical
|
HRD (Homologous Recombination Deficiency) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
|
HRD
|
FoundationOne® CDx • Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit • TruSight Tumor 170 Assay
|
irinotecan
1m
Clinical and Genomic Characterization of ERBB2-Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort. (PubMed, JCO Glob Oncol)
The prevalence of lithiasis seems to be higher in Chilean versus US patients with GBC. A similar prevalence of ERBB2 alterations of overall 14% and better OS suggests that a proportion of them could benefit from human epidermal growth factor receptor type 2-targeted therapies. The smaller cohort of Chile, where the disease prevalence is higher, is a reminder and invitation for the need of more robust next-generation sequencing analyses globally.
Journal • Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 mutation • HER-2 fusion
|
MSK-IMPACT
1m
Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi® Tablets), a covalently-binding, irreversible FGFR1-4 inhibitor (PubMed, Nihon Yakurigaku Zasshi)
Although some typical FGFR inhibitor-related side effects were observed, they were manageable and futibatinib had a good safety profile. Futibatinib is an important drug for biliary tract cancer, which has limited treatment options; its development is underway for other types of cancer, and it is expected to benefit more patients.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion • FGFR mutation • FGFR wild-type
|
Lytgobi (futibatinib)
1m
Usefulness of multigene liquid biopsy of bile for identifying driver genes of biliary duct cancers. (PubMed, Cancer Sci)
Of the biliary tract cancer cases examined with this method, 13 (54%) and 4 (17%) resulted in positive cancer driver mutation detection in the bile and plasma cfDNAs, respectively. These results suggest that bile is a more reliable source for LB than plasma for multigene panel analyses of biliary tract cancers.
Journal • Liquid biopsy • Biopsy
|
LiquidPlex™
2ms
Aberrant Expression of Pneumocytic Markers (TTF-1 and Napsin-A) in Biliary Duct and Gallbladder Adenocarcinomas; A Potential Diagnostic Pitfall. (PubMed, Int J Surg Pathol)
We herein report uncommon instances of strong and diffuse expression of these markers in two examples of adenocarcinomas arising from the bile duct and gallbladder. A review of the literature and a summary of similar studies relating to aberrant TTF-1 and Napsin-A expression in biliary tract adenocarcinomas are presented.
Journal
|
NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
2ms
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets. (PubMed, ESMO Open)
In addition to the most common alterations such as isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations, fibroblast growth factor receptor 2 (FGFR2) fusions, and alterations, we will also discuss less frequently encountered alterations such as BRAF V600E mutation and neurotrophic tyrosine kinase receptor gene (NTRK) fusion. We highlight the importance of molecular profiling in guiding therapeutic decisions and emphasize the need for continued research to optimize and expand targeted treatment strategies for this aggressive malignancy.
Review • Journal • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • BRAF V600 • FGFR2 mutation • FGFR2 fusion • IDH mutation + BRAF V600E
2ms
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data. (PubMed, Cancer Immunol Immunother)
This study confirms the phase 3 trial results of durvalumab with platinum and gemcitabine, providing a substantial real-world dataset with detailed molecular characterization. No specific patient subgroup showed a markedly better response to durvalumab based on conventional NGS panels. Further research is needed to explore the link between immunotherapy responses and molecular subgroups.
Clinical data • Retrospective data • Journal • Real-world evidence • Real-world
|
HRD (Homologous Recombination Deficiency)
|
Imfinzi (durvalumab) • gemcitabine
2ms
Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine. (PubMed, Oncologist)
Tepotinib showed remarkable efficacy in treating MET-amplified intrahepatic cholangiocarcinoma, underscoring the importance of molecular profiling in BTCs and suggesting a potential new therapeutic approach for this rare cancer subtype.
Journal • PD(L)-1 Biomarker • Metastases
|
TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
TP53 mutation • MET amplification • MET mutation
|
cisplatin • Imfinzi (durvalumab) • gemcitabine • Tepmetko (tepotinib)
2ms
Immune cells mediate the causal pathway linking circulating complements to cancer: A Mendelian randomization study. (PubMed, Inflamm Res)
This study revealed the causal relationships between complement components and certain cancers, with five immune cells as potential mediators.
Journal • Immune cell
|
IL2RA (Interleukin 2 receptor, alpha) • CD93 (CD93 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • CEACAM8 (CEA Cell Adhesion Molecule 8) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
2ms
New P3 trial
|
5-fluorouracil • capecitabine • irinotecan • leucovorin calcium • gemcitabine oral (D07001)
2ms
New P2 trial
|
Ariely (adebrelimab) • HRS-4642